ProCE Banner Activity

Expert Answers to Frequently Asked Questions About Chronic Lymphocytic Leukemia and COVID-19

Text Module
Read expert answers to key questions asked by clinicians during a series of live Webinars focused on the interface of CLL and the COVID-19 pandemic, including COVID-19 outcomes in patients with CLL, minimizing COVID-19 risk, selecting CLL treatments during the pandemic, BTK and PI3K inhibition in patients with COVID-19, and considerations for when a COVID-19 vaccine is available.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.

Share

Faculty

Jacqueline Barrientos

Jacqueline Barrientos, MD, MS

Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Attending Physician
Division of Hematology/Oncology
Northwell Health System
Lake Success, New York

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Jacob D. Soumerai

Jacob D. Soumerai, MD

Instructor
Attending Physician

Department of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Jacqueline Barrientos, MD, MS

Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Attending Physician
Division of Hematology/Oncology
Northwell Health System
Lake Success, New York

Jacqueline Barrientos, MD, MS, has disclosed that she has received funds for research support from Oncternal; consulting fees from AstraZeneca, Bayer, Genentech, Gilead Sciences, and Sandoz; and other financial or material support from Janssen.

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, Juno, MingSight, Oncternal, TG Therapeutics, and Verastem and consulting fees from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Gilead Sciences, Janssen, Juno, and Pharmacyclics.

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, BeiGene, Gilead Sciences, Loxo Oncology, and Pharmacyclics.

Jacob D. Soumerai, MD

Instructor
Attending Physician

Department of Medicine
Harvard Medical School
Boston, Massachusetts

Jacob D. Soumerai, MD, has disclosed that he has received funds for research support from BeiGene, BostonGene, Genentech/Roche, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, and Verastem.